Jefferies Maintains Buy on Amarin

Jefferies is out with its report today on Amarin

, maintaining Buy. In a note to clients, Jefferies writes, "We had an opportunity to spend time with AMRN senior management to discuss potential scenarios for a pharma partnership or acquisition, AMR101 regulatory filings, and the CV outcomes study required to file for an ANCHOR indication. We continue to believe in a multi-billion market opportunity for AMR101, and AMRN remains one of our top biotech picks." At the time of posting, shares of AMRN were trading pre-market at $19.84, up 1.74% from Friday's close.